- $11.61bn
- $11.25bn
- $1.19bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 72.41 | ||
| PEG Ratio (f) | 1.7 | ||
| EPS Growth (f) | 73.97% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 9.57 | ||
| Price to Tang. Book | 11.16 | ||
| Price to Free Cashflow | 77.22 | ||
| Price to Sales | 9.36 | ||
| EV to EBITDA | 191.63 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 2.62% | ||
| Return on Equity | 3.5% | ||
| Operating Margin | 3.03% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 560.41 | 747.59 | 847.13 | 1,058.52 | 1,194.62 | 1,354.98 | 1,557.83 | 16.89% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | -36.87 | +111.44 | +35.93 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
Directors
- Adam Elsesser CHM (59)
- Maggie Yuen CFO (49)
- James Pray CEX (57)
- Johanna Roberts EVP (49)
- Lynn Rothman EVP (60)
- Lambert Shiu CAO (41)
- Arani Bose OTH (59)
- Janet Leeds LED (59)
- Harpreet Grewal IND (54)
- Don Kassing IND (79)
- Bridget O'rourke IND (53)
- Surbhi Sarna IND (35)
- Thomas Wilder IND (57)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- June 21st, 2004
- Public Since
- September 18th, 2015
- No. of Shareholders
- 22
- No. of Employees
- 4,500
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
New York Stock Exchange- Shares in Issue
- 38,725,940
- Address
- One Penumbra Place, ALAMEDA, 94502
- Web
- https://www.penumbrainc.com/
- Phone
- +1 5109952486
- Auditors
- Deloitte & Touche LLP
Upcoming Events for PEN
Penumbra Inc Annual Shareholders Meeting
Q2 2025 Penumbra Inc Earnings Release
Similar to PEN
Abbott Laboratories
New York Stock Exchange
Agilent Technologies
New York Stock Exchange
Alcon AG
New York Stock Exchange
Artivion
New York Stock Exchange
Avanos Medical
New York Stock Exchange
FAQ
What is the Penumbra share price?
As of Today at 22:35 UTC, shares in Penumbra are trading at $299.78. This share price information is delayed by 15 minutes.
How has the Penumbra share price performed this year?
Shares in Penumbra last closed at $299.78 and the price had moved by +45.88% over the past 365 days. In terms of relative price strength the Penumbra share price has outperformed the S&P500 Index by +34.65% over the past year.
What are the analyst and broker recommendations for Penumbra?
The overall consensus recommendation for Penumbra is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Penumbra dividend yield?
Penumbra does not currently pay a dividend.
Does Penumbra pay a dividend?
Penumbra does not currently pay a dividend.
When does Penumbra next pay dividends?
Penumbra does not currently pay a dividend.
How do I buy Penumbra shares?
To buy shares in Penumbra you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Penumbra?
As of the previous close price of $299.78, shares in Penumbra had a market capitalisation of $11.61bn.
Where are Penumbra shares listed?
Here are the trading details for Penumbra:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: PEN
What kind of share is Penumbra?
Based on an overall assessment of its quality, value and momentum Penumbra is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Penumbra share price forecast for 2025?
The analyst consensus target price for shares in Penumbra is $318.88. That is 6.37% above the last closing price of $299.78.
Analysts covering Penumbra currently have a consensus Earnings Per Share (EPS) forecast of $3.72 for the next financial year.
Find out moreWhat is the trend in the Penumbra share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Penumbra. Over the past six months, its share price has outperformed the S&P500 Index by +54.35%.
As of the last closing price of $299.78, shares in Penumbra were trading +28.25% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Penumbra PE Ratio?
The Penumbra PE ratio based on its reported earnings over the past 12 months is 72.41. The shares last closed at $299.78.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Penumbra?
Penumbra's management team is headed by:
- Adam Elsesser - CHM
- Maggie Yuen - CFO
- James Pray - CEX
- Johanna Roberts - EVP
- Lynn Rothman - EVP
- Lambert Shiu - CAO
- Arani Bose - OTH
- Janet Leeds - LED
- Harpreet Grewal - IND
- Don Kassing - IND
- Bridget O'rourke - IND
- Surbhi Sarna - IND
- Thomas Wilder - IND